1. Home
  2. PIM vs NYXH Comparison

PIM vs NYXH Comparison

Compare PIM & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Master Intermediate Income Trust

PIM

Putnam Master Intermediate Income Trust

N/A

Current Price

$3.05

Market Cap

153.2M

Sector

Finance

ML Signal

N/A

Logo Nyxoah SA

NYXH

Nyxoah SA

N/A

Current Price

$1.54

Market Cap

165.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PIM
NYXH
Founded
1988
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Finance Companies
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
153.2M
165.0M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PIM
NYXH
Price
$3.05
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$9.33
AVG Volume (30 Days)
53.6K
263.6K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
8.28%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
$61.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.04
$1.26
52 Week High
$3.50
$6.87

Technical Indicators

Market Signals
Indicator
PIM
NYXH
Relative Strength Index (RSI) 35.53 49.78
Support Level $3.07 $1.49
Resistance Level $3.21 $1.70
Average True Range (ATR) 0.04 0.08
MACD -0.01 -0.00
Stochastic Oscillator 30.89 27.78

Price Performance

Historical Comparison
PIM
NYXH

About PIM Putnam Master Intermediate Income Trust

Putnam Master Intermediate Income Trust is a closed-end fund. Its investment objective is to provide high current income and relative stability of net asset value. The fund pursues its goal by investing in U.S. high-grade, high-yield, and international fixed-income securities with limited maturities. The fund's portfolio includes the United States Government and agency mortgage obligations; mortgage-backed securities; corporate bonds and notes, and foreign government and agency bonds and notes.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: